Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Budesonide/glycopyrronium bromide/formoterol

From Wikipedia, the free encyclopedia
Combination drug

Pharmaceutical compound
Budesonide/glycopyrronium bromide/formoterol
Combination of
BudesonideInhaled corticosteroid
Glycopyrronium bromideAnticholinergicmuscarinic antagonist
FormoterolLong-acting β2 agonist
Clinical data
Trade namesBreztri Aerosphere, Trixeo Aerosphere, Riltrava Aerosphere
Other namesBudesonide/glycopyrrolate/formoterol fumarate
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
administration
By mouth (inhalation)
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Budesonide/glycopyrronium bromide/formoterol, sold under the brand nameBreztri Aerosphere among others, is an inhalable fixed-dosecombination medication for the treatment ofchronic obstructive pulmonary disease (COPD).[5][6][7] It containsbudesonide,glycopyrronium bromide, andformoterol fumarate dihydrate.[5][6][7] It isinhaled.[5][6][7]

The most common side effects includeoral candidiasis (a fungal infection of the mouth),upper respiratory tract infection,pneumonia, back pain, muscle spasms, influenza,urinary tract infection, cough, sinusitis, anddiarrhea.[5] Headache is also a common side effect.[6][7]

The combination was approved for medical use in the United States in July 2020,[8][9] and in the European Union in December 2020.[6]

Medical uses

[edit]

Budesonide/glycopyrronium bromide/formoterol isindicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.[5][6][7]

Society and culture

[edit]

Legal status

[edit]

Trixeo Aerosphere was authorized for medical use in the European Union in December 2020.[6] Riltrava Aerosphere was authorized for medical use in the European Union in January 2022.[7]

Propellant

[edit]

In 2025, a new budesonide/glycopyrronium bromide/formoterol inhaler using the propellantHFO-1234ze(E) was approved in the United Kingdom, for the treatment ofCOPD.[10]

In July 2025, theEuropean Medicines Agency recommended a change in the composition of Trixeo Aerosphere and its duplicate product Riltrava Aerosphere to replace the existing gas propellant with a low global warming potential gas alternative.[11] The low global warming potential alternative propellant has a 1000-fold reduction in global warming potential and similar physical properties.[11]

See also

[edit]

References

[edit]
  1. ^"Health product highlights 2021: Annexes of products approved in 2021".Health Canada. 3 August 2022. Retrieved25 March 2024.
  2. ^"Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension - Summary of Product Characteristics (SmPC)".(emc). Retrieved12 November 2021.
  3. ^"Trimbow NEXThaler (DPI) 88 micrograms/5 micrograms/9 micrograms per actuation inhalation powder - Summary of Product Characteristics (SmPC)".(emc). 6 September 2021. Retrieved12 November 2021.
  4. ^"Trimbow pMDI 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution - Summary of Product Characteristics (SmPC)".(emc). 4 June 2021. Retrieved12 November 2021.
  5. ^abcdef"Breztri- budesonide, glycopyrrolate, and formoterol fumarate aerosol, metered".DailyMed. Retrieved15 September 2020.
  6. ^abcdefgh"Trixeo Aerosphere EPAR".European Medicines Agency (EMA). 13 October 2020. Retrieved5 January 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^abcdefg"Riltrava Aerosphere EPAR".European Medicines Agency. 10 November 2021. Retrieved20 May 2022.
  8. ^"Breztri Aerosphere approved in the US for the maintenance treatment of COPD".AstraZeneca (Press release). 24 July 2020. Retrieved15 September 2020.
  9. ^"Drug Approval Package: Breztri Aerosphere".U.S.Food and Drug Administration (FDA). 1 July 2021. Retrieved20 May 2022.
  10. ^"MHRA approves world's first low-carbon version of COPD inhaler Trixeo Aerosphere".GOV.UK.
  11. ^ab"First reformulation of an inhaled medicine with environmentally friendly gas propellant".European Medicines Agency (EMA) (Press release). 25 July 2025. Retrieved28 July 2025.
Adrenergics,inhalants
Short-acting β2 agonists
Long-acting β2 agonists
Ultra-long-acting β2 agonists
Other
Glucocorticoids
Anticholinergics/
muscarinic antagonist
Mast cell stabilizers
Xanthines
Eicosanoid inhibition
Leukotriene antagonists
Arachidonate 5-lipoxygenase inhibitors
Thromboxane receptor antagonists
Non-xanthinePDE4 inhibitors
Others/unknown
Combination products
Products
Predecessors and
acquired companies
People
Portal:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Budesonide/glycopyrronium_bromide/formoterol&oldid=1315802074"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp